TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients

Inclusion Criteria: 1. Subject has no contraindication to chemotherapy, and has no obvious obstacles in the function of major organs such as heart, lung, liver and kidney; 2. Subject has middle-advanced liver cancer of Barcelona Clinic Liver Cancer stages B/C ; 3. Liver function child-pugh class A or B; Karnofsky (KPS) score \> 60 points; 4. Subject could not accept surgical resection or refuse surgical operation;and who did not receive other treatment before operation. 5.18\~75 years old; ECOG PS score: 0-1 points; expected survival period is more than 3 months. Exclusion Criteria: 1. Subject has contraindications to chemotherapy; 2. Subject has obstacle in the function of major organs such as heart, lung, liver and kidney; 3. Severe coagulation dysfunction (prothrombin time \> 18 s or hemorrhagic tendency); 4. Uncontrollable hypertension and portal hypertension; 5. Hepatic artery-portal vein or hepatic vein fistula or portal vein trunk cancer thrombus; 6. A large amount of ascites or refractory ascites; 7. With distant metastasis.